EGFR and breast cancer: 177Lu-anti-EGFR (300 MBq/kg) in combination with docetaxel and doxorubicin reduced the growth rate of MDA-MB-231 and HCI-002 BC xenografts by 83 days vs. 52 days when the BC xenografts were treated with 177Lu-anti-EGFR alone.